constitute several FDA-approved drugs for cancer treatment. In this work, a new set of 2-(2-(substituted) hydrazinyl)-4-(1-methyl-1H-benzo[d]imidazol-2-yl) thiazoles 4a-q were designed as epidermal growth factor receptor (EGFR) inhibitors and synthesized using concise synthetic methods. The new target compounds have been evaluated in vitro for their suppression activity against EGFR TK. Compounds 4n, 4h
杂环如
噻唑和
苯并咪唑被认为是特权结构,因为它们构成了几种
FDA批准的用于癌症治疗的药物。在这项工作中,设计了一组新的2-(2-(取代)
肼基)-4-(
1-甲基-1 H-
苯并[ d ]
咪唑-2-基)
噻唑4a-q作为
表皮生长因子受体(
EGFR)
抑制剂,并使用简明的合成方法合成。已经在体外评估了新的目标化合物对
EGFR TK的抑制活性。化合物4n,4h,4i,4a和4d与作为参考药物的
厄洛替尼相比,具有显着的效力(IC50,71.67–152.59 nM; IC50
厄洛替尼,152.59 nM)。此外,M
TT分析表明,化合物4j,4a,4f,4h,4n对人乳腺癌
细胞系(
MCF-7)产生了最有希望的细胞毒性作用(IC50; 5.96-11-1.91 µM;
厄洛替尼IC50; 4.15 µM)。化合物4a作为
EGFR TK
抑制剂和抗乳腺癌药物显示出有希望的活性。此外,4a诱导凋亡作用,并在G2 / M